Search Results - "Higashiyama, Ryoko Inaba"

Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients by Ohuchi, Mayu, Yagishita, Shigehiro, Jo, Hitomi, Akagi, Kazumasa, Inaba Higashiyama, Ryoko, Masuda, Ken, Shinno, Yuki, Okuma, Yusuke, Yoshida, Tatsuya, Goto, Yasushi, Horinouchi, Hidehito, Makino, Yoshinori, Yamamoto, Noboru, Ohe, Yuichiro, Hamada, Akinobu

“…•PPK model of 200 mg Q3W pembrolizumab in Japanese patients with NSCLC is developed.•Early change in CL of pembrolizumab correlated with treatment effect and…”
Get full text

Response to dabrafenib plus trametinib on a rare BRAF mutation (V600_W604 deletion–insertion R) in an advanced non‐small cell lung cancer patient by Tamura, Akiko, Inaba Higashiyama, Ryoko, Yoshida, Tatsuya, Satozono, Yaya, Ohe, Yuichiro

“…Although dabrafenib plus trametinib has been approved for BRAF V600E mutation positive advanced non‐small cell lung cancer (NSCLC), data on its efficacy…”
Get full text

Clinical outcomes of pembrolizumab therapy in advanced‐NSCLC patients with poor performance status (≥3) and high PD‐L1 expression (TPS ≥50%): A case series by Inaba‐Higashiyama, Ryoko, Yoshida, Tatsuya, Jo, Hitomi, Shirasawa, Masayuki, Motoi, Noriko, Ohe, Yuichiro

“…Pembrolizumab is the standard first‐line treatment for advanced non‐small cell lung cancer (NSCLC) with programmed death‐ligand 1 (PD‐L1) expression tumor…”
Get full text

Atypical radiological presentation of pulmonary invasion of diffuse large B-cell lymphoma mimicking Pneumocystis jiroveci pneumonia by Higashiyama, Ryoko Inaba, Makita, Shinichi, Maeshima, Akiko Miyagi, Maruyama, Dai

Get full text

In Response: Letter Received From Dr. Charles Ricordel Titled "Safety of Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors for Advanced NSCLC" by Higashiyama, Ryoko Inaba, Yoshida, Tatsuya, Yagishita, Shigehiro, Hamada, Akinobu

Get more information

Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC by Higashiyama, Ryoko Inaba, Yoshida, Tatsuya, Yagishita, Shigehiro, Ohuchi, Mayu, Sakiyama, Naomi, Torasawa, Masahiro, Shirasawa, Masayuki, Masuda, Ken, Shinno, Yuki, Matsumoto, Yuji, Okuma, Yusuke, Goto, Yasushi, Horinouchi, Hidehito, Yamamoto, Noboru, Hamada, Akinobu, Ohe, Yuichiro

“…Administration of 400 mg pembrolizumab every 6 weeks (400 mg Q6W) has been approved on the basis of the results of simulated pharmacokinetic modeling and…”
Get more information

Non-specific symptoms as a prodrome of immune-related adverse events in patients with non-small cell lung cancer receiving nivolumab: a consecutive analysis of 200 patients by Higashiyama, Ryoko Inaba, Horinouchi, Hidehito, Kuchiba, Aya, Matsumoto, Yuji, Murakami, Shuji, Goto, Yasushi, Kanda, Shintaro, Fujiwara, Yutaka, Yamamoto, Noboru, Ohe, Yuichiro

“…Purpose Immune checkpoint blockade therapy is the standard treatment for metastatic or refractory non-small cell lung cancer (NSCLC). However, it is associated…”
Get full text

Ileal perforation at the site of peritoneal metastasis with intestinal infiltration by dual EGFR-VEGF pathway inhibition in an EGFR-mutant non-small cell lung cancer patient by SANOMACHI, Tomomi, YOSHIDA, Tatsuya, HIGASHIYAMA, Ryoko INABA, SATOZONO, Yaya, MATSUNAGA, Shiho, KANEMITSU, Yukihide, OHE, Yuichiro

“…Gastrointestinal (GI) perforation including ileal perforation is a rare complication of antivascular endothelial growth factor (anti-VEGF) therapy. Risk…”
Get full text

Implications of EGFR expression in MAPK dependency and adaptive immunity status of EGFR -mutated lung adenocarcinoma by Torasawa, Masahiro, Yoshida, Tatsuya, Shiraishi, Kouya, Yagishita, Shigehiro, Uehara, Yuji, Miyakoshi, Jun, Higashiyama, Ryoko Inaba, Mochizuki, Akifumi, Matsumoto, Yuji, Shinno, Yuki, Okuma, Yusuke, Goto, Yasushi, Horinouchi, Hidehito, Hamamoto, Ryuji, Yamamoto, Noboru, Watanabe, Shun-ichi, Yatabe, Yasushi, Takahashi, Kazuhisa, Kohno, Takashi, Ohe, Yuichiro

“…8028 Background: EGFR expression (EGFR-exp) varies among patients (pts) with EGFR-mutated (m EGFR) NSCLC. It remains unknown how EGFR-exp status influences…”
Get full text

Efficacy of nivolumab in patients treated by corticosteroid due to immune-related adverse events by Higashiyama, Ryoko Inaba, Horinouchi, Hidehito, Sekine, Katsutoshi, Matsumoto, Yuji, Murakami, Shuji, Goto, Yasushi, Kanda, Shintaro, Fujiwara, Yutaka, Yamamoto, Noboru, Ohe, Yuichiro

“…Abstract only 163 Background: Nivolumab is a standard treatment for metastatic or refractory non-small cell lung cancer (NSCLC). Because immune-related adverse…”
Get full text